List of Excipients in Branded Drug VERELAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	VERELAN	verapamil hydrochloride	54868-2200	D&C RED NO. 28
Physicians Total Care Inc	VERELAN	verapamil hydrochloride	54868-2200	FD&C BLUE NO. 1
Physicians Total Care Inc	VERELAN	verapamil hydrochloride	54868-2200	FD&C RED NO. 40
Physicians Total Care Inc	VERELAN	verapamil hydrochloride	54868-2200	FERRIC OXIDE YELLOW
Physicians Total Care Inc	VERELAN	verapamil hydrochloride	54868-2200	FUMARIC ACID
Physicians Total Care Inc	VERELAN	verapamil hydrochloride	54868-2200	GELATIN

Verelan Excipient Strategy and Commercial Opportunities for Verapamil Extended-Release Capsules

Last updated: August 2, 2026

Verelan is an extended-release oral capsule containing verapamil hydrochloride, a calcium-channel blocker used primarily for hypertension and angina. Its commercial value is tied to controlled drug release rather than novel pharmacology. The main opportunity is a technically robust generic or 505(b)(2) product that reproduces the release profile, limits food and alcohol sensitivity, and reduces manufacturing cost through multiparticulate coating and excipient optimization.

The strongest excipient strategy is based on coated pellets or drug-containing beads using a water-insoluble polymer, a pore-forming or hydrophilic component, and a capsule-fill system that supports dose proportionality across strengths. Commercial opportunities exist in generic substitution, authorized-generic supply, reformulation, lower-cost manufacturing, and differentiated once-daily verapamil delivery.

What is Verelan and how is it formulated?

Verelan contains verapamil hydrochloride in extended-release capsules. The product is designed to release verapamil over an extended period after oral administration, avoiding the rapid plasma concentration changes associated with immediate-release tablets or capsules.

Verelan product profile

Attribute	Product information
Active ingredient	Verapamil hydrochloride
Dosage form	Extended-release capsule
Route	Oral
Therapeutic class	Calcium-channel blocker
Primary uses	Hypertension and angina
Strengths historically marketed	120 mg, 180 mg, and 240 mg
Release technology	Multiparticulate extended-release system
Reference product status	FDA-approved prescription product
Primary competitive products	Generic verapamil hydrochloride extended-release capsules and tablets
Key technical hurdle	Matching dissolution and pharmacokinetic behavior across strengths

The product uses a multiparticulate system rather than relying solely on a matrix tablet. Multiparticulate delivery permits distribution of drug among numerous particles, which can reduce the impact of localized defects and provide more controlled release than a simple immediate-release capsule fill.

FDA labeling identifies inactive ingredients for the marketed product. Depending on the specific product, strength, manufacturer, and capsule shell, the formulation may include sugar spheres, hypromellose, ethylcellulose, povidone, talc, magnesium stearate, gelatin, titanium dioxide, and permitted colorants. Exact composition must be confirmed against the current FDA label and manufacturer-specific inactive-ingredient record because generic products do not necessarily use the same excipient system as Verelan.[1,2]

What excipients control Verelan release?

The core release mechanism is likely based on coated drug-loaded pellets. Each excipient has a defined technical role.

Drug-layering excipients

Sugar spheres or other inert starter cores provide a reproducible surface for drug layering. A binder such as povidone helps attach verapamil hydrochloride to the cores. Hypromellose can function as both a binder and a film-forming polymer.

The commercial advantages are:

• Controlled particle-size distribution
• Uniform drug loading
• Lower risk of dose segregation
• Compatibility with fluid-bed coating
• Easier scale-up than a highly compressed matrix system

The main manufacturing risks are agglomeration, overwetting, spray-drying, and uneven drug distribution. These risks affect content uniformity and dissolution.

Release-controlling polymers

Ethylcellulose is a water-insoluble polymer commonly used to control diffusion from coated pellets. It can be applied as a membrane, often with a pore former or hydrophilic polymer. The coating thickness, polymer grade, plasticizer level, and curing conditions determine the release rate.

Hypromellose may provide a hydrophilic pathway that accelerates water penetration. Povidone or another water-soluble component can increase membrane permeability. Talc can reduce tackiness during coating and improve powder handling.

The formulation must balance four variables:

1. Drug loading on each pellet
2. Coating weight gain
3. Polymer permeability
4. Mechanical integrity during encapsulation and gastrointestinal transit

A thicker or less permeable ethylcellulose membrane generally slows release. Higher levels of pore-forming excipient generally accelerate release. These relationships are not linear after scale-up because coating uniformity, pellet bed movement, and curing can alter dissolution.

Capsule-shell excipients

Gelatin is commonly used for hard capsules. Titanium dioxide and colorants provide opacity and product identification. Capsule-shell selection affects moisture transfer, brittleness, appearance, and stability.

A vegetarian or hypromellose capsule could create a differentiated product, but it would require stability, dissolution, and regulatory comparability work. Capsule-shell substitution is commercially attractive only if it improves supply reliability, patient acceptability, or market access.

What excipient strategy is best for a generic Verelan product?

A generic developer should prioritize a multiparticulate formulation that uses widely available compendial excipients and avoids dependence on a single specialized polymer supplier.

Recommended formulation architecture

Formulation layer	Preferred function	Candidate excipient classes
Starter core	Particle support	Sugar spheres or microcrystalline cellulose spheres
Drug layer	Adhesion and uniformity	Povidone, hypromellose
Seal coat	Separation and mechanical protection	Hypromellose or other film former
Rate-controlling coat	Extended release	Ethylcellulose
Pore-forming phase	Release adjustment	Hypromellose, povidone, water-soluble polymers
Anti-tacking agent	Processing control	Talc
Capsule shell	Containment and identification	Gelatin or hypromellose

The highest-value development work is not the selection of novel excipients. It is the optimization of coating weight, polymer ratio, pellet-size distribution, and capsule-fill composition.

How can excipient selection reduce development risk?

A developer can reduce risk by using:

• USP/NF-grade ethylcellulose with established pharmaceutical use
• Standardized sugar-sphere particle-size grades
• A single binder across all strengths
• A common pellet platform with proportional capsule fills
• Low-peroxide excipient grades where oxidative sensitivity is a concern
• Excipient suppliers with dual manufacturing sites
• Robust in-process controls for spray rate, atomization, inlet temperature, and bed temperature

Using the same pellet platform across 120 mg, 180 mg, and 240 mg strengths can reduce the number of formulation variables. Dose proportionality may be achieved by changing capsule fill weight or the ratio of active pellets to inert pellets. That approach must be confirmed by dissolution and bioequivalence studies.

What formulation patents protect Verelan technology?

Verelan’s formulation technology historically related to controlled-release verapamil delivery, including multiparticulate systems and extended-release oral dosage forms. The relevant intellectual-property categories include:

• Coated pellet and bead systems
• Controlled-release polymer membranes
• Drug-layering processes
• Once-daily verapamil release profiles
• Capsule systems containing multiple release populations
• Methods of treating hypertension or cardiovascular disease with extended-release verapamil

The principal commercial question is whether enforceable patent claims remain relevant to a new product. Verapamil itself is an old active ingredient, and basic composition-of-matter protection is no longer a barrier. Any remaining risk would arise from formulation, manufacturing, or method-of-use claims rather than the molecule.

Patent status must be evaluated by claim, jurisdiction, terminal disclaimer, PTA or PTE, maintenance status, and litigation history. The USPTO Patent Center and FDA Orange Book should be reviewed for the specific reference-listed drug and patent records.[3,4]

When does Verelan lose exclusivity?

Verelan’s active ingredient is long off-patent. Market exclusivity therefore depends on product-specific patents, FDA regulatory exclusivity, and the commercial status of generic approvals.

Exclusivity category	Relevance to Verelan
New chemical entity exclusivity	Expired or not relevant to current competition
Basic molecule patent	Expired
Formulation patents	Potentially relevant only if unexpired and claim scope applies
Method-of-use patents	Potentially relevant to labeled indications
Pediatric exclusivity	Must be checked in FDA records
Orphan exclusivity	Not generally associated with Verelan
Generic approval exclusivity	May apply to an individual ANDA applicant if FDA grants it
Data exclusivity	Not a meaningful current barrier for an old active ingredient

FDA Orange Book listings can change as patents expire, are delisted, or are subject to litigation outcomes. A commercial diligence review should rely on the current edition, not historical patent lists.[3]

What is the Orange Book status of Verelan?

Verelan should be assessed through the FDA Orange Book by reference-listed-drug application, strength, dosage form, and listed patents. The Orange Book identifies approved drug products, therapeutic equivalence codes, and certain patent and exclusivity information. It does not establish that every formulation patent provides a meaningful barrier to a technically different generic product.

For a generic entrant, the relevant regulatory pathway is generally an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A Paragraph IV certification may be required if an Orange Book-listed patent is asserted to be invalid, unenforceable, or not infringed.[3,5]

Which companies are challenging Verelan?

Generic verapamil extended-release products have historically been supplied by multiple manufacturers, including large generic companies and specialized capsule manufacturers. The competitive set can include products from companies such as Mylan, Teva, Sandoz, Actavis, and other FDA-approved generic manufacturers, depending on the strength and current marketing status.

The relevant competitive analysis is not limited to the number of approved ANDAs. It should distinguish:

• Approved but unmarketed ANDAs
• Actively marketed generic products
• Authorized-generic supply
• Products with therapeutic-equivalence ratings
• Products discontinued for commercial or manufacturing reasons
• Suppliers with active shortage or back-order exposure

FDA’s Drugs@FDA database, Orange Book, and FDA drug-shortage records are the primary sources for current approval and supply status.[3,6]

What Paragraph IV challenges and litigation affect Verelan?

A Paragraph IV challenge would be commercially significant only if an unexpired Orange Book patent remains listed against the relevant Verelan application. For an old verapamil product, the most likely patent risks relate to extended-release formulation architecture or manufacturing methods rather than the active ingredient.

Potential litigation issues include:

• Whether pellet coating claims cover a generic’s polymer system
• Whether a generic’s dissolution profile falls within a claimed release range
• Whether a manufacturing process claim is infringed
• Whether a listed patent is properly submitted to the Orange Book
• Whether a settlement restricts launch timing or supply arrangements
• Whether a product has a section viii carve-out for a method of use

No current litigation conclusion should be inferred solely from historical patent listings. Litigation and settlement status must be checked in PACER, FDA patent records, and company filings before investment or licensing decisions.[3,7]

What generic entry risks exist for Verelan?

The principal risks are technical and commercial.

Bioequivalence risk

Extended-release verapamil products can be sensitive to food, gastrointestinal transit, and release kinetics. A product may match dissolution in standard media but fail pharmacokinetic equivalence under fed or fasting conditions.

Alcohol dose-dumping risk

Alcohol can alter polymer permeability or accelerate drug release from certain modified-release systems. A generic developer should include alcohol-challenge dissolution testing in product development and regulatory strategy.

Strength-scaling risk

A formulation that works at 120 mg may not scale predictably to 180 mg or 240 mg. Capsule fill volume, pellet loading, and gastric emptying can affect the release profile.

Manufacturing risk

Fluid-bed coating is sensitive to spray rate, atomization pressure, drying conditions, and pellet circulation. Small process changes can create meaningful dissolution shifts.

Commercial risk

The market is mature and price-sensitive. A new entrant needs either low manufacturing cost, reliable supply, a contract-manufacturing advantage, or a differentiated presentation. A technically successful product without a supply or channel strategy may have limited value.

What commercial opportunities exist for Verelan excipients?

Generic supply

The largest opportunity is a reliable, low-cost generic capsule platform. A manufacturer with established multiparticulate coating capacity can leverage existing equipment and excipient procurement.

505(b)(2) reformulation

A 505(b)(2) product could pursue a differentiated delivery profile, capsule shell, dosing schedule, or patient-use characteristic. Possible concepts include:

• A lower-volume capsule
• A sprinkle formulation, if technically and clinically justified
• A vegetarian capsule
• An alcohol-resistant release system
• A formulation with improved storage stability
• A product optimized for patients with swallowing difficulty

These products would face greater clinical and regulatory expense than a conventional ANDA.

Excipient supplier partnerships

Suppliers can create value through:

• High-uniformity sugar spheres
• Low-moisture starter cores
• Consistent ethylcellulose grades
• Ready-to-use coating dispersions
• Contract coating and encapsulation services
• Dual-source excipient qualification packages

A supplier that provides both excipient material and process support may gain a stronger position than a commodity excipient vendor.

Contract manufacturing

Verelan-type products are suitable for contract manufacturers with fluid-bed coating, pellet classification, capsule filling, and modified-release analytical capability. The same platform may support other extended-release products, improving equipment utilization.

How strong is the Verelan patent estate?

The underlying molecule has little remaining exclusivity value. The patent estate is best characterized as formulation- and process-dependent, with practical strength determined by the survival of specific claims and the ability to design around them.

Patent layer	Current strategic value
Verapamil composition of matter	Low
Basic oral dosage form	Low
Multiparticulate release system	Moderate if valid claims remain
Specific polymer membrane	Moderate, usually design-around possible
Manufacturing process	Variable
Method of treating hypertension	Generally limited for ANDA competition through labeling carve-outs
Trade secrets and process know-how	Potentially meaningful even without patent protection

The commercial moat is more likely to come from process capability, reproducible dissolution, regulatory knowledge, and customer relationships than from broad exclusionary patent rights.

How does Verelan compare with other extended-release calcium-channel blockers?

Verelan competes indirectly with amlodipine, nifedipine extended-release, diltiazem extended-release, and other antihypertensive products. Verapamil has additional use in selected cardiovascular settings but also has clinically important interaction and tolerability considerations.

Product category	Primary differentiation	Generic pressure	Formulation opportunity
Verapamil ER	Extended release and cardiovascular profile	High	Pellet coating, dose flexibility
Diltiazem ER	Multiple ER technologies and broad product base	High	Capsule, tablet, bead systems
Nifedipine ER	Long-acting dihydropyridine therapy	High	Osmotic and matrix technologies
Amlodipine	Long half-life and simple dosing	Very high	Limited formulation differentiation

Verelan is more technically demanding than a simple immediate-release product because release kinetics are central to product performance. That technical complexity can limit the number of successful manufacturers, even when patent barriers are weak.

What is the revenue exposure and launch outlook?

Verelan is a mature product, so revenue exposure is generally concentrated in:

• Prescription volume retained by the brand
• Generic price erosion
• Contract supply reliability
• Pharmacy substitution
• Product discontinuation risk
• Reimbursement and formulary positioning

A conventional ANDA launch would likely face rapid price competition if several therapeutically equivalent products are active. A differentiated 505(b)(2) product could support better pricing but would require evidence that the new formulation provides a clinically or operationally meaningful advantage.

The most attractive launch scenario is a low-cost generic with a qualified second-source excipient strategy, strong dissolution control, and commercial access to wholesalers and pharmacy networks. The highest-risk scenario is a novel reformulation that requires extensive clinical work without a clear pricing premium.

Key Takeaways

1. Verelan is a verapamil hydrochloride extended-release capsule whose value depends on controlled release, not new-molecule exclusivity.
2. The most relevant excipients are drug-layering binders, ethylcellulose release-control membranes, hydrophilic pore formers, talc, and capsule-shell materials.
3. A multiparticulate pellet platform is the most practical generic development strategy.
4. The principal technical risks are dissolution matching, alcohol dose dumping, fed-state bioequivalence, and strength scaling.
5. Current patent and Orange Book exposure must be reviewed at the specific application and claim level.
6. Generic competition is likely to be intense because verapamil is an old active ingredient.
7. Commercial opportunities remain in reliable generic supply, excipient dual sourcing, contract coating, and selected 505(b)(2) reformulations.
8. Process capability and regulatory execution are likely to create more value than broad patent rights.

FAQs

Can ethylcellulose be replaced in a generic Verelan formulation?

Yes. A developer can use another release-controlling polymer or polymer combination if the resulting product meets dissolution and bioequivalence requirements and avoids applicable patent claims. Replacement is a development decision, not a simple excipient substitution.

Is Verelan suitable for a sprinkle formulation?

Potentially, but the pellet system must maintain dose uniformity, release performance, stability, and acceptable administration through soft food or liquid. FDA labeling and clinical-use instructions would need to support the presentation.

Does a Verelan generic need to match every inactive ingredient?

No. An ANDA generally does not need to duplicate every excipient. It must demonstrate pharmaceutical equivalence, bioequivalence, quality, and compliance with applicable safety and labeling requirements.

Can a new capsule shell create market exclusivity?

A capsule shell alone rarely creates meaningful exclusivity. It may support differentiation, but commercial protection would depend on patentable claims, regulatory exclusivity, or a demonstrable clinical or adherence advantage.

Which excipient creates the greatest supply-chain risk?

Ethylcellulose and specialized pellet cores can create greater qualification and supply risk than common binders or lubricants. Dual sourcing and supplier-specific process validation are important for commercial continuity.

References

1. U.S. Food and Drug Administration. (n.d.). Verelan: Verapamil hydrochloride extended-release capsules prescribing information. Drugs@FDA.

2. U.S. National Library of Medicine. (n.d.). DailyMed: Verelan and verapamil hydrochloride extended-release capsule labeling. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

5. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

7. Public Access to Court Electronic Records. (n.d.). PACER case locator. https://pcl.uscourts.gov/